Fengcai Zhu

15.2k total citations · 4 hit papers
240 papers, 6.2k citations indexed

About

Fengcai Zhu is a scholar working on Infectious Diseases, Epidemiology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Fengcai Zhu has authored 240 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Infectious Diseases, 104 papers in Epidemiology and 52 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Fengcai Zhu's work include SARS-CoV-2 and COVID-19 Research (69 papers), Viral gastroenteritis research and epidemiology (53 papers) and Viral Infections and Immunology Research (50 papers). Fengcai Zhu is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (69 papers), Viral gastroenteritis research and epidemiology (53 papers) and Viral Infections and Immunology Research (50 papers). Fengcai Zhu collaborates with scholars based in China, United States and Taiwan. Fengcai Zhu's co-authors include Jingxin Li, Lunbiao Cui, Hongxing Pan, Kai Chu, Yiyue Ge, Baoli Zhu, Bin Wu, Zhenglun Liang, Changgui Li and Yuemei Hu and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Fengcai Zhu

231 papers receiving 6.0k citations

Hit Papers

Safety, tolerability, and immunogenicity of an inactivate... 2020 2026 2022 2024 2020 2020 2021 2023 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
    2020 937 citations Hongxing Pan, Kai Chu et al. profile →
  2. Co-infection with respiratory pathogens among COVID-2019 cases
    2020 419 citations Fengcai Zhu, Lunbiao Cui et al. profile →
  3. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
    2021 173 citations Hongxing Pan, Kai Chu et al. profile →
  4. Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials
    2023 68 citations Fengcai Zhu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fengcai Zhu China 38 3.6k 2.0k 913 791 729 240 6.2k
Martin Petric Canada 47 3.4k 0.9× 3.4k 1.7× 570 0.6× 715 0.9× 352 0.5× 123 7.1k
John J. Treanor United States 51 3.0k 0.8× 5.9k 2.9× 593 0.6× 1.3k 1.6× 329 0.5× 126 8.2k
Anton M. van Loon Netherlands 47 2.9k 0.8× 4.9k 2.4× 1.6k 1.8× 472 0.6× 417 0.6× 184 7.7k
Stephen L. Cochi United States 47 2.5k 0.7× 2.6k 1.3× 1.8k 2.0× 240 0.3× 140 0.2× 124 6.4k
Fausto Baldanti Italy 55 5.8k 1.6× 7.1k 3.4× 965 1.1× 900 1.1× 435 0.6× 434 12.3k
Michael G. Ison United States 51 2.9k 0.8× 5.7k 2.8× 454 0.5× 546 0.7× 551 0.8× 234 8.5k
Roland W. Sutter United States 49 5.0k 1.4× 2.0k 1.0× 4.7k 5.2× 321 0.4× 143 0.2× 186 7.5k
Ralf Clemens Germany 39 2.0k 0.5× 2.3k 1.1× 742 0.8× 503 0.6× 932 1.3× 140 4.9k
Lindsey R. Baden United States 56 5.9k 1.6× 5.0k 2.4× 393 0.4× 1.1k 1.4× 985 1.4× 230 10.7k
Jonathan B. Gubbay Canada 37 3.4k 0.9× 3.8k 1.9× 391 0.4× 967 1.2× 62 0.1× 172 6.9k

Countries citing papers authored by Fengcai Zhu

Since Specialization
Citations

This map shows the geographic impact of Fengcai Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengcai Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengcai Zhu more than expected).

Fields of papers citing papers by Fengcai Zhu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fengcai Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengcai Zhu. The network helps show where Fengcai Zhu may publish in the future.

Co-authorship network of co-authors of Fengcai Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Fengcai Zhu. A scholar is included among the top collaborators of Fengcai Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fengcai Zhu. Fengcai Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cheng, Xin, Hongxing Pan, Zhijian Wang, et al.. (2025). Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial. Human Vaccines & Immunotherapeutics. 21(1). 2448405–2448405. 1 indexed citations
2.
Han, Xu, Hongxing Pan, Pengfei Jin, et al.. (2024). A head-to-head comparison of humoral and cellular immune responses of five COVID-19 vaccines in adults in China. Frontiers in Immunology. 15. 1455730–1455730. 1 indexed citations
3.
Zheng, Hui, Cuidan Li, Aihua Yao, et al.. (2024). Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19. Frontiers in Immunology. 15. 1461419–1461419. 1 indexed citations
4.
Zhang, Jinlong, Xue Wang, Zhe Zhang, et al.. (2023). Safety and Immunogenicity of Homologous Recombinant Adenovirus Type 5-Vectored COVID-19 Vaccine Booster Dose in Healthy Adults Aged 18–60 Years: a Single-Center, Open-Label Trial. Infectious Diseases and Therapy. 12(12). 2757–2769. 1 indexed citations
5.
Xia, Xin, Zhongming Tan, Rong Tang, et al.. (2023). Environmental Impact Assessment for the Use of an Orally Aerosolized Adenovirus Type-5 Vector-Based COVID-19 Vaccine in Randomized Clinical Trials. The Journal of Infectious Diseases. 228(6). 715–722. 1 indexed citations
6.
7.
Kharrat, Ashraf, Fengcai Zhu, Xiang Y. Ye, et al.. (2021). Factors associated with antibiotic administration delay among preterm infants with late-onset bloodstream infection. Journal of Hospital Infection. 120. 31–35. 1 indexed citations
8.
Wang, Kang, Li Zhang, Lunbiao Cui, et al.. (2020). Serotype specific epitopes identified by neutralizing antibodies underpin immunogenic differences in Enterovirus B. Nature Communications. 11(1). 15 indexed citations
9.
Wang, Kang, Ling Zhu, Yao Sun, et al.. (2020). Structures of Echovirus 30 in complex with its receptors inform a rational prediction for enterovirus receptor usage. Nature Communications. 11(1). 4421–4421. 18 indexed citations
10.
Zhang, Dawei, et al.. (2019). [Research progress of maternal immunization].. PubMed. 53(5). 534–539. 2 indexed citations
11.
Zhu, Jia-Hong, Xiaohong Wu, Yuhua Li, Fengcai Zhu, & Yuemei Hu. (2018). Investigation on the effects of booster immunization of human diploid cell rabies vaccine after eight years of primary vaccination. 32(3). 233–236. 1 indexed citations
12.
Hong, Tao, Yuemei Hu, Xing Wu, et al.. (2017). A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine. Vaccine. 35(37). 5073–5080. 40 indexed citations
13.
Gao, Fan, Lianlian Bian, Xin Yao, et al.. (2017). Seroepidemiology of coxsackievirus B5 in infants and children in Jiangsu province, China. Human Vaccines & Immunotherapeutics. 14(1). 74–80. 18 indexed citations
14.
15.
Jin, Pengfei, et al.. (2016). Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months. Human Vaccines & Immunotherapeutics. 12(4). 916–921. 18 indexed citations
16.
Liu, Jin, Feng Chen, Fengcai Zhu, et al.. (2015). Evaluation of vaccine seroresponse rates and adverse event rates through Bayesian and frequentist methods. Human Vaccines & Immunotherapeutics. 11(6). 1557–1563. 2 indexed citations
17.
Li, Jingxin, et al.. (2015). [Epidemiological characteristics of enterovirus type 71 diseases].. PubMed. 36(1). 45–8. 1 indexed citations
18.
Huo, Xiang, Xian Qi, Fenyang Tang, et al.. (2011). Seroprevalence of Pandemic (H1N1) 2009 in Pregnant Women in China: An Observational Study. PLoS ONE. 6(3). e17995–e17995. 3 indexed citations
19.
Gu, Jiang, Yanqing Liu, Shu Yu, et al.. (2009). Enterohemorrhagic Escherichia coli trivalent recombinant vaccine containing EspA, intimin and Stx2 induces strong humoral immune response and confers protection in mice. Microbes and Infection. 11(10-11). 835–841. 36 indexed citations
20.
Zhao, Jingxin, Fengcai Zhu, Yuelong Shu, et al.. (2005). [Preliminary study on nasal spray of interferon alpha-2b used for prevention of rubella and measles virus infections].. PubMed. 19(3). 220–2.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin Petric Breakdown of academic impact, for papers by John J. Treanor Breakdown of academic impact, for papers by Anton M. van Loon Breakdown of academic impact, for papers by Stephen L. Cochi Breakdown of academic impact, for papers by Fausto Baldanti Breakdown of academic impact, for papers by Michael G. Ison Breakdown of academic impact, for papers by Roland W. Sutter Breakdown of academic impact, for papers by Ralf Clemens Breakdown of academic impact, for papers by Lindsey R. Baden Breakdown of academic impact, for papers by Jonathan B. Gubbay
Rankless by CCL
2026